

1 **Endothelial CXCL12 regulates neovascularization during tissue repair and tumor progression**

2 **Authors**

3 Zeshaan N. Maan, MD, MSc, MRCS¹, Michael S. Hu, MD, MPH, MS^{1†}, Robert Rennert, MD^{1†}, Janos
4 A. Barrera, MD¹, Dominik Duscher, MD¹, Michael Januszyk, MD, PhD¹, Alexander Whittam, BA¹,
5 Jagannath Padmanabhan PhD¹, Nicholas Vial, MD¹, Natalie Ho¹, Lauren H. Fischer, MD¹, Johannes
6 Riegler, PhD², Joseph C. Wu, MD, PhD², Michael T. Longaker, MD, MBA¹, Geoffrey C. Gurtner, MD,
7 FACS^{1*}

8

9 †These authors contributed equally to this work.

10

11 **Affiliations**

12 ¹Department of Surgery, Division of Plastic and Reconstructive Surgery, Stanford University School of
13 Medicine, Stanford, California, USA

14

15 ²Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA

16

17

18

19 Short Title: Endothelial cell CXCL12 regulates tissue repair

20

21

22 ***Corresponding Author:**

23 Geoffrey C. Gurtner, MD, FACS

24 Professor and Associate Chairman of Surgery

25 Stanford University School of Medicine

26 Department of Surgery, Division of Plastic and Reconstructive Surgery

27 257 Campus Drive West, Hagey building GK-201

28 Stanford, CA 94305-5148

29 Phone: (650) 724 - 6672

30 Fax: (650) 724 - 9501

31 E-mail: ggurtner@stanford.edu

32

33

34

35 **Abstract**

36
37 CXC chemokine ligand 12 (CXCL12; stromal cell-derived factor 1 [SDF-1]), primarily known for its role
38 in embryogenesis and hematopoiesis, has also been implicated in tumor biology and neovascularization.
39 However, its specific role and mechanism of action remain poorly understood. We previously
40 demonstrated that CXCL12 expression is Hypoxia-Inducible Factor (HIF)-1 responsive. Here we use a
41 conditional CXCL12 knockout mouse to show that endothelial-specific deletion of CXCL12 (eKO) does
42 not affect embryogenesis, but reduces the survival of ischemic tissue, altering tissue repair and tumor
43 progression. Loss of vascular endothelial CXCL12 disrupts endothelial – fibroblast crosstalk necessary
44 for stromal growth and vascularization. Single-cell gene expression analysis in combination with a
45 parabiosis model reveals a specific population of non-inflammatory circulating cells, defined by genes
46 regulating neovascularization, which is recruited by endothelial CXCL12. These findings indicate an
47 essential role for endothelial CXCL12 expression during the adult neovascular response in tissue injury
48 and tumor progression.

49

50

51

52 **Introduction**

53
54 Adult neovascularization (new blood vessel growth in response to ischemia) plays a crucial role in tissue
55 repair and regeneration and influences functional outcomes after injury to the heart, brain, and periphery
56 . The complex biological processes governing neovascularization and tissue repair are exploited by tumor
57 cells (Carmeliet et al., 2011; Hanahan et al., 2011), which typically exist in a setting of relative ischemia
58 (Helmlinger et al., 1997). It is increasingly apparent that tumor survival and progression critically relies
59 on the stromal microenvironment (Li et al., 2003). While numerous studies have explored the importance
60 of a vascularized stroma to both physiologic tissue repair and pathologic tumor development (Valkenburg
61 et al., 2018), an insufficient understanding of the underlying molecular mechanisms has limited the
62 development of effective therapeutics to target this process.

63

64 Our laboratory and others have previously described the pivotal role of Chemokine (C-X-C motif) ligand
65 12 (CXCL12) in the recruitment of circulating cells to hypoxic tissue, secondary to stabilization of
66 Hypoxia-Inducible Factor (HIF)-1 (Ceradini et al., n.d.), and regulation of stem cell microenvironments
67 (Ding et al., 2013; Greenbaum et al., 2013). Interestingly, CXCL12 is also widely expressed in a number
68 of human tumors and has a role in tumor progression and survival (Feig et al., 2013; Orimo et al., 2005;
69 Teicher et al., 2010). These reports suggest a critical role for CXCL12 in both tissue repair and tumor
70 progression, two physiological processes that depend on a delicate orchestration of molecular and cellular
71 factors that govern neovascularization. The mechanisms underlying the influence of CXCL12 on these
72 seemingly disparate processes remains unknown. We hypothesized that interrogating the role of CXCL12
73 in neovascularization would provide an opportunity to unravel the complex molecular mechanisms that
74 underlie these processes.

75

76 Here we use a conditional CXCL12 knockout mouse to identify a critical role for vascular endothelial
77 specific CXCL12 expression in neovascularization and tumor progression. Knockout of endothelial-
78 specific CXCL12 inhibits wound healing and ischemic tissue survival. Surprisingly, loss of endothelial
79 CXCL12 expression completely abrogates tumor growth despite high levels of continued CXCL12
80 expression by both tumor cells and tumor-associated fibroblasts. We demonstrate that loss of endothelial
81 CXCL12 inhibits fibroblast proliferation, survival, and expression of angiogenic cytokines, clarifying the
82 importance of endothelial-fibroblast cross-talk in this process. Finally, utilizing single-cell gene
83 expression analyses in combination with a parabiosis model, we identify a non-inflammatory progenitor
84 cell subpopulation exclusively recruited to tissue by endothelial CXCL12 signaling. These data reveal a
85 crucial role for vascular endothelial-derived CXCL12 in both tissue repair and tumor progression and
86 uncover a paracrine mechanism governing the formation of vascularized stroma.

87
88
89

90 **Results**

91

92 *Vascular endothelial derived CXCL12 does not regulate embryogenesis or vasculogenesis*

93 To specifically assess the role of endothelial CXCL12 during neovascularization, we engineered a floxed
94 allele of *Cxcl12* (*Cxcl12* *loxP/loxP*) (Figure 1A). *Rosa-creER* and *Tie2-cre* transgenes were utilized to
95 generate tamoxifen-inducible global CXCL12 knockout (gKO) and endothelial-cell-specific (Ding et al.,
96 2013; Greenbaum et al., 2013; Kisanuki et al., 2001) CXCL12 knockout (eKO) mice (Figure 1B),
97 respectively. CXCL12 knockout progeny (*CXCL12*^{*loxP/loxP*}; *ROSA-creER*^{*+/−*}, *Tie2-cre* ^{*+/−*}) were viable,
98 fertile, produced at expected Mendelian ratios and showed no overt pathologic phenotype. We confirmed
99 DNA recombination upon tamoxifen administration with a subsequent >80% decrease in mRNA and
100 protein expression of CXCL12 (Figure 1C-E). Endothelial specific knockout of CXCL12 was additionally
101 validated used immunostaining (Figure 1F). Prior work has demonstrated that stromal expression of
102 CXCL12 is critical during embryogenesis (Nagasawa et al., 1996), cardiac development (Nagasawa et al.,
103 1996; Tachibana et al., 1998), hematopoiesis (Nagasawa et al., 1996), and organ vascularization
104 (Tachibana et al., 1998). Immunostaining and standard histology were utilized to examine organ
105 development and vascularization in eKO mice and demonstrated normal morphology and vascular pattern
106 (Supplementary Figure 1). This suggests that endothelial CXCL12 does not have a primary role during
107 organogenesis and vascular development.

108

109

110




111

112

113

114

115



116

117 **Figure 1. Development and validation of gKO and eKO CXCL12 mice.**

118 (A) Schematic of the murine *Cxcl12* locus depicting our approach to homologous recombination in
119 embryonic stem cells to generate a floxed *Cxcl12* allele. *Cxcl12* floxed mice were crossed with mice
120 carrying the *Cre-recombinase* transgene to generate tissue-specific knockout progeny) (B) Schematic of
121 the breeding strategy used to generate tamoxifen inducible global *Cxcl12* knockout (gKO) and
122 endothelial-cell specific *Cxcl12* knockout (eKO) mice. (C) PCR validation of the presence and
123 recombination of the floxed allele upon exposure of gKO mice to tamoxifen. (D) qRT-PCR of *Cxcl12*
124 expression in the skin of tamoxifen induced gKO mice compared to control. (E) ELISA for *Cxcl12* levels
125 in the skin of tamoxifen induced gKO mice compared to control. (F) Immunohistochemical analysis
126 showing overlapping expression of CXCL12 and CD31 in wild type but not eKO mice. Images obtained
127 with a Zeiss Axioplan 2 fluorescence microscope, magnification x20, scale bar 200 μ m.

128
129
130

131 *Vascular endothelial CXCL12 critically regulates neovascularization and tissue repair.*

132 We then investigated the role of CXCL12 in adult tissue repair using an excisional cutaneous injury model

133 in eKO and gKO mice (Galiano et al., 2004). We found that both eKO and gKO mice showed delayed

134 healing of their wounds compared to floxed control mice (16 days vs. 11 days, respectively) (Figure 2A,

135 B). The impairment in tissue repair in both knockout groups was apparent by the 4th day after injury, as

136 measured by remaining wounded area (Figure 2C). The similar healing times of eKO and gKO mice

137 (Figure 2A-C) suggests that endothelial cells are the critical source of CXCL12 during the repair of injured

138 tissue in adults. Microscopically, the most obvious difference in the healed tissue of eKO mice was a

139 decreased vascular density by immunostaining (Figure 2D, E). We analyzed the injured tissue at earlier

140 time points and found reduced transcription and protein expression of CXCL12 in eKO mice. In addition,

141 VEGF and FGF-2 transcription and protein expression were diminished (Figure 2F-H), suggesting that


142 the CXCL12 signaling modulates other HIF-1 regulated, angiogenic signaling pathways. To confirm the

143 critical role of endothelial CXCL12 signaling during neovascularization, we used a dorsal ischemic skin

144 flap model (Ceradini et al., n.d.), which demonstrated decreased tissue survival in eKO versus wild type

145 mice (Figure 3A-D). Similarly, using a myocardial ischemia model (Patten et al., 1998), in which the left

146 coronary artery is ligated, there was decreased myocardial vessel density in eKO mice (Figure 3E,F).




148 **Figure 2. Wound healing relies on endothelial CXCL12.**

149 (A) Representative images of similarly delayed healing in endothelial specific (eKO) and global CXCL12
150 knockout (gKO) mice compared to wild type (WT). (B, C) Both eKO and gKO mice require 16 days to
151 heal compared to 11 days in control. (D, E) Decreased vascular density in fully healed wounds of eKO
152 mice. Images obtained with a Zeiss Axioplan 2 fluorescence microscope, magnification x20, scale bar 200
153 μm . (F) Decreased expression of *Ccx112* (top), *Vegf* (middle), and *Fgf2* (bottom) in the wounds of eKO
154 mice. (G, H) Selective loss of CXCL12 (top) and decreased levels of VEGF (middle) and FGF-2 (bottom)
155 in eKO mice. Magnification x20, scale bar 200 μm .

156

157

158



159

160 **Figure 3. Endothelial CXCL12 regulates neovascularization, stroma formation, and tumor
161 progression.**

162 (A, B) Decreased ischemic skin flap survival in eKO mice. (C, D) Decreased vascular density in
163 ischemic tissue of eKO mice. Images obtained with a Zeiss Axioplan 2 fluorescence microscope,
164 magnification x20, scale bar 200 μ m. (E, F) Decreased vascular density in peri-infarct zone of eKO
165 myocardium. (PI = peri-infarct zone; I = infarct zone). Magnification x20, scale bar 200 μ m. (G, H)
166 Significantly reduced tumor burden in eKO mice. (fKO = fibroblast specific CXCL12 knockout) (I, J)
167 Decreased fibroblast expression of VEGF and FGF-2 in the presence of decreased endothelial
168 expression of CXCL12. (K, L, M) Increased fibroblast proliferation, migratory capacity, and survival
169 (mediated by PI3K/AKT signaling) in response to CXCL12. Images obtained with a Zeiss Axioplan 2
170 fluorescence microscope, magnification x20, scale bar 200 μ m.

171

172 *Tumor growth is dependent on host vascular endothelial CXCL12 expression*

173 Cancer cells, which typically exist in the setting of relative ischemia (Helmlinger et al., 1997) appear to
174 rely on the stromal microenvironment for tumor growth, angiogenesis, and invasion (Li et al., 2003). In
175 particular, melanoma has been shown to rely on its surrounding stroma (Flach et al., 2011) and CXCL12,
176 typically derived from cancer cells, has been implicated in tumor progression and survival (Teicher et al.,
177 2010), including in B16 murine melanoma cells (Mendt et al., 2017). To determine if host endothelial
178 CXCL12 had a role in tumor stroma formation and tumor progression, we transplanted B16 murine
179 melanoma cells into control, eKO, and fibroblast-specific (*Colla2-creER* transgene) (Ubil et al., 2014;
180 Zheng et al., 2002) CXCL12 knockout (fKO) mice. The fKO model was chosen in order to study whether
181 stromal cells themselves produce CXCL12 in sufficient amounts to drive tumor progression, independent
182 of endothelial cell or other circulatory sources. Tumor measurements demonstrated completely abrogated
183 tumor growth only in eKO mice (Figure 3G, H), suggesting a pivotal role for host endothelial CXCL12 in
184 tumor progression.

185

186 *Vascular endothelial CXCL12 regulates fibroblast gene expression, proliferation and migration*

187 The establishment of new vascularized tissue, or stroma, requires a coordinated interplay between
188 endothelial cells and fibroblasts (Fukumura et al., 1998; Newman et al., 2011; Stratman et al., 2009). To
189 explore the role of CXCL12 in endothelial – fibroblast cross talk, we used siRNA to target CXCL12 in
190 human microvascular endothelial cells co-cultured with normal human dermal fibroblasts. Decreasing
191 endothelial production of CXCL12 reduced fibroblast expression of VEGF and FGF-2 in response to
192 hypoxia (Figure 3I, J). These data suggest that hypoxia-responsive fibroblast expression of VEGF and
193 FGF-2, which stimulate endothelial cells to proliferate and form new vessels, is in turn reliant on vascular
194 endothelial expression of CXCL12 and provide a possible mechanism for our earlier immunostaining


195 results in injured eKO skin (Figure 2F-H). Additionally, VEGF has been shown to impart drug resistance
196 to tumor endothelial cells within the tumor stroma (Hida et al., 2013), which suggests that endothelial
197 CXCL12 may induce drug resistance in tumors through a paracrine mechanism. Next, we treated
198 fibroblasts with recombinant CXCL12 and demonstrated increased proliferation and migratory capacity
199 (Figure 3K, L). CXCL12 also enhanced the survival of fibroblasts in a low nutrient environment (Figure
200 3M). It has become increasingly evident that the tumor microenvironment plays a critical role in cancer
201 progression and treatment outcomes. Collectively, these data reveal a novel mechanism by which host
202 endothelial CXCL12 governs the formation of a critical component of this microenvironment and,
203 therefore, tumor progression.

204

205 *Vascular endothelial CXCL12 recruits a unique non-inflammatory circulating cell to injured tissue*
206 Because the endothelium is the primary interface between the circulation and the tissue it supplies, and as
207 endothelial cells are crucial for inflammatory cell recruitment (Lawrence et al., 1991; Möhle et al., 1998),
208 we asked whether endothelial specific CXCL12 has a role in the recruitment of non-inflammatory
209 circulating cells that may participate in the neovascularization of hypoxic tissue. Wild type and eKO
210 recipient mice were parabiosed to GFP positive donor mice and cross-circulation was confirmed after 3
211 weeks using fluorescent imaging and FACS analysis (Figure 4A). Excisional wounds were subsequently
212 created on the dorsum of eKO recipient mice and demonstrated reduced recruitment of mature
213 hematopoietic lineage negative (Ly6C/G, CD45R, TER119, CD4, CD8, and CD11b), GFP positive cells
214 (Figure 4B,C), which would include all types of progenitor cells and exclude inflammatory cells such as
215 neutrophils and lymphocytes. To better characterize the progenitor cells differentially recruited to eKO
216 and control recipient mice, we utilized microfluidic technology to apply a massively parallel single cell
217 transcriptional analysis (SCA) (Supplementary Figure 2, Supplementary Figure 3). Partitional clustering

218 revealed four transcriptionally distinct subpopulations of non-inflammatory progenitor cells in injured
219 tissue. One of these subpopulations (cluster 2) was completely absent in eKO mice, while another was
220 reduced in eKO mice. The remaining two populations were preserved across control and eKO mice (Figure
221 4D, Supplementary Figure 4, Supplementary Figure 5). The subpopulation completely absent from injured
222 eKO tissue was defined by increased expression of genes associated with progenitor cells, such as Ckit
223 and Mcam, and vascular genes, such as Pecam1, Flt1, Tie1, and Tek. Additionally, this population
224 differentially expressed the cellular adhesion gene Itgb3 (Figure 4E). Pathway analysis software was used
225 to generate a transcriptional network utilizing those genes differentially expressed in this cluster as seed
226 genes. “Inferred” genes included those known to be implicated in cell survival (Erk1/2, Akt, NfkB
227 complex), neovascularization (Vegf, Pdgfb), and extracellular matrix interactions (Fak). The overall
228 associated biological functions of this network included Cardiovascular System Development and
229 Function, Cellular Movement, and Cell Morphology (Figure 4F). Collectively, these data indicate that
230 endothelial CXCL12 signaling regulates the recruitment of a unique non-inflammatory circulating cell to
231 injured tissue.

232



234

235 **Figure 4. Endothelial CXCL12 regulates recruitment of progenitor cells in ischemic tissue.**

236 (A) Parabiosis schema and demonstration of cross-circulation. Images obtained with a Zeiss Axioplan 2
237 fluorescence microscope, magnification x20, scale bar 200 μ m. (B, C) Decreased recruitment of non-
238 inflammatory circulating cells to wounds of eKO mice. (D) Single-cell analysis demonstrating absence
239 of sub-population of non-inflammatory circulating cells from wounds of eKO mice. (E) Differentially
240 expressed genes defining cell population absent from eKO wounds. Left bar for each panel represents
241 fraction of cells that failed to amplify. (F) Top scoring Ingenuity Pathway Analysis (IPA)-constructed
242 transcriptome network based on population defining “seed” genes (E). Seed genes are colored in red,
243 inferred genes in grey.

244

245 **Discussion**

246 We describe the differential function of CXCL12 depending on its physiological context and tissue of
247 origin: endothelial expression does not regulate organ development or vascularization during
248 embryogenesis, in contrast to stromal CXCL12 expression (Tachibana et al., 1998), but it does influence
249 the expression of hypoxia-responsive, angiogenic genes and regulates the neovascular response during
250 both the repair of injured tissue and tumor progression. Although the chemotactic effect of CXCL12 in
251 the context of leukocytes has been investigated (Campbell et al., 1998), its physiological function and
252 cellular source in the context of injury had not been previously elucidated. We propose that a distinct
253 population of circulating, non-inflammatory progenitor cells that originate from the bone marrow are
254 exclusively trafficked to injured tissue by CXCL12 mediated angiocrine signaling.

255

256 Our findings extend previous work examining the relationship between tumor pathobiology and the
257 mechanisms underlying tissue repair (tumor/wound). Targeting the tumor microenvironment is an
258 emerging paradigm in the management of resistant tumors. Our results demonstrate that host CXCL12
259 critically regulates the microenvironment independent of tumor derived CXCL12, presenting a potential
260 target for clinical therapy. However, it remains unclear why the selective inactivation of CXCL12 in
261 endothelial cells has such profound effects on tumor growth despite expression of CXCL12 by several
262 other cell types, including tumor endothelial cells. Our findings may also have implications for the
263 development of personalized oncological therapies, as understanding patient-specific biological responses
264 to cancer may be more crucial than tumor profiling. While this study does not exhaustively explore the
265 mechanisms underlying the similar effects of endothelial CXCL12 on tumor growth and tissue repair,
266 there is increasing evidence in the literature of the molecular and cellular similarities between wound

267 healing and tumorigenesis (Arwert et al., 2012; Flier et al., 1986; Schäfer et al., 2008). Further research
268 parsing out potential differences are likely necessary to inform the development of clinical therapies.

269 **Materials and Methods**

270 **Mice**

272 All transgenic strains had been backcrossed at least ten generations onto a C57BL/6 background (Jackson
273 Laboratories, Bar Harbor, ME). *Rosa-creER*, *Tie2-cre*(14) and *Colla2-creER* mice were obtained from
274 the Jackson Laboratory. GFP positive *C57BL/6-Tg(CAG-EGFP)1Osb/J* mice were similarly obtained
275 from Jackson Laboratory. Mice were maintained under standard pathogen-free conditions according to
276 methods approved by the Stanford University Administrative Panel on Laboratory Animal Care (APLAC).
277 All animal experiments were compliant with ethical regulations and approved by the Stanford University
278 APLAC.

279

280 **Generation of CXCL12^{loxP/loxP} Mice**

281 A floxed allele of *Cxcl12* was generated by inserting *LoxP* sites flanking exon 2 of *Cxcl12*. FRT sites were
282 inserted flanking the neomycin selection cassette (Figure 1). Generation of targeted embryonic stem cells
283 and blastocyst injections were performed as previously described (Greenbaum et al., 2013). Excision of
284 the neomycin cassette was accomplished through FLP-FRT recombination. Mice were genotyped using
285 PCR primers: *Cxcl12^{loxP}* forward, 5'-ACCCATAAATTGAAACATTGG-3'; *Cxcl12^{loxP}* reverse, 5'-
286 TTCTACCACCTGCAGTTTCC-3'; *Cxcl12^{loxP}* recombined, 5'-GGTAAATTATCGAATTCCGAA-
287 3'.

288

289 **Animal Studies**

290 Animal studies were performed with n=5 animals, and repeated at least twice, unless otherwise specified.
291 Mice were 12-16 weeks of age at start of experiments.

292

293 *Murine Excisional Wound Model*

294 Splinted excisional wounds were created as previously described (Galiano et al., 2004). Briefly, using a
295 6-mm biopsy punch (Integra Miltex, Plainsboro, NJ), two 6-mm full thickness wounds were created on
296 the shaved dorsum of anesthetized mice. In parabiotic pairs, the recipient mouse was only wounded on
297 the non-parabiosed side. A donut-shaped silicone splint (10-mm diameter) was centered on the wound and
298 secured to the skin using an immediate-bonding adhesive (Krazy Glue; Elmer's Inc., Columbus, Ohio)
299 and 6-0 nylon sutures (Ethicon Inc. Somerville, NJ) to prevent wound contraction. All wounds were
300 covered using an occlusive dressing (Tegaderm; 3M, St. Paul, MN). Following surgery, the mice were
301 placed on warming pads and allowed to fully recover from anesthesia before being returned to the
302 institutional animal facility. Digital photographs were taken at regular intervals and wound area was
303 measured using ImageJ software (NIH) (n = 6 mice). All measurements were performed by a blinded
304 observer. Wound tissue was harvested on post-wounding day 7 and once wounds were completely healed
305 using an 8mm punch biopsy.

306

307 *Murine Ischemic Skin Flap Model*

308 A reproducible model of graded soft tissue ischemia was created on the dorsum of mice as previously
309 described (Valkenburg et al., 2018). Briefly, a full thickness (epidermis, dermis, and underlying adipose
310 tissue) 3-sided peninsular flap (1.25 x 2.5 cm) was created on the shaved dorsum. The flap was elevated
311 from the underlying muscular bed and a 0.13 mm thick silicone sheet was inserted to separate the skin
312 from the underlying tissue. The skin flap was sutured back into place with 6-0 nylon sutures. This model
313 creates a gradient of increasing ischemia from proximal to distal. Digital photographs were taken at regular
314 intervals and necrosed area was measured using ImageJ software (NIH) (n = 6 mice). All measurements
315 were performed by a blinded observer.

316 *Murine Myocardial Infarction Model*

317 Ligation of the mid left anterior descending (LAD) artery was performed by a single experienced surgeon
318 (JR) as previously described (Patten et al., 1998). Infarction was confirmed by myocardial blanching and
319 EKG changes. Animals were euthanized and hearts explanted at postoperative day 30 (n=6 mice, repeated
320 once).

321

322 *Murine Parabiosis Model*

323 GFP positive “donor” and either control or eKO “recipient” mice were shaved and anesthetized. Parabiosis
324 surgery was performed as previously described (n=5 mice analyzed) (Bunster et al., 1933; Wagers et al.,
325 2002). Briefly, the corresponding flanks of mice were shaved and disinfected with betadine solution and
326 70% ethanol. Matching skin incisions were made from the olecranon to the knee joint of each mouse. The
327 skin edges were undermined to create about 1 cm of free skin. 6-0 nylon sutures were used to approximate
328 the dorsal and ventral skin. The skin was over-sewn to protect the suture line. Mice were allowed to
329 recover as described above. Buprenorphine was used for analgesia by subcutaneous injection every 8–12
330 hours for 48 hours post operation. After three weeks, cross-circulation was confirmed using fluorescent
331 microscopy and FACS analysis (Figure 4A).

332

333 *Murine Tumor Model*

334 A 1 cm incision was created on the right flank of shaved and anesthetized control, eKO, and fKO mice. A
335 1x1 cm subcutaneous pocket was created and a hydrogel (Wong et al., 2010) seeded with 2.5×10^5 B16-
336 F10 melanoma cells (ATCC CRL-6475) was implanted and the incision closed with 6-0 nylon suture.
337 Measurements for length, width, and height were taken with a digital caliper and tumor volume was
338 calculated using the formula: $V = 0.5 \times (L \times W \times H)$, where V is tumor volume, L is length, W is width,

339 and H is height. Tumor sizes were measured by the same, blinded observer every other day until mice
340 were euthanized at 4 weeks.

341

342 **Blood and Skin Analysis**

343 Mononuclear cells from blood were obtained from the buffy coat layer following Ficol-Paque density
344 centrifugation (Jaatinen et al., 2007). Skin samples, including wounded tissue and ischemic skin, were
345 digested and cells isolated as previously described (Suga et al., 2014).

346

347 **Histology and Tissue Analysis**

348 For fixation, tissues were placed in 2% paraformaldehyde for 12-16 hours at 4°C. Samples were prepared
349 for embedding by soaking in 30% sucrose in PBS at 4°C for 24 hours. Samples were removed from the
350 sucrose solution and tissue blocks were prepared by embedding in Tissue Tek O.C.T (Sakura Finetek) on
351 dry ice. Frozen blocks were mounted on a MicroM HM550 cryostat (MICROM International GmbH) and
352 5-8 micron thick sections were transferred to Superfrost/Plus adhesive slides (Fisher & Company, Inc.).

353

354 **Immunohistochemistry**

355 For hematoxylin and eosin staining, standardized protocols were used with no modifications. Sections
356 were visualized using Leica DM4000B microscope (Leica Microsystems). Immunostaining on frozen
357 sections was performed using the following primary antibodies: CD31 (Abcam 28364), SDF-1 (Abcam
358 25117), VEGF (Abcam 52917), and FGF-2 (Abcam 8880). Briefly, slides were fixed in cold acetone (-
359 20°C), and then blocked for 1 hour in 5% goat serum at room temperature followed by incubation with
360 primary antibody for 12-16 hours at 4°C. Slides were then incubated for 1 hour with goat anti-rabbit Alexa
361 Fluor 488 conjugate (Invitrogen A-11034) or 594 conjugate (Invitrogen A-11037). A Zeiss Axioplan 2

362 fluorescence microscope was used to image the slides (Carl Zeiss, Inc., Thornwood, NY). Quantification
363 of fluorescence was performed by a blinded observer using ImageJ software (NIH).

364

365 **Flow Cytometry**

366 All flow cytometry analysis was performed on dissociated wound tissue or blood. Cells were stained by
367 standard protocols with the following fluorescently conjugated antibodies (eBiosciences unless otherwise
368 noted). Lineage analysis was assessed using R-Phycoerythrin (PE)-Cy5-conjugated Ly6C/G (RB6-8C5,
369 Gr-1, myeloid), CD45R (RA3-6B2, B220, B lymphocytes), TER119, CD4, CD8, and CD11b. Cells not
370 stained with these antibodies were incubated with the proper isotype controls or left unstained. Cells were
371 resuspended in FACS buffer and DAPI prior to FACS analysis on a FACSaria II. At least 50,000 events
372 were recorded per sample. Data were analyzed using FlowJo digital fluorescence-activated cell sorting
373 software by a single blinded evaluator (Tree Star Inc, Ashland, OR).

374

375 **Quantitative Reverse-Transcription PCR**

376 RNA was isolated using an RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's
377 instructions. Reverse transcription was performed with 500 ng RNA using the SuperScript III First-Strand
378 Synthesis System (Invitrogen, Carlsbad, CA). qRT-PCR was carried out using TaqMan® Assays-on-
379 Demand™ Gene Expression Products from Applied Biosystems (Foster City, CA, USA): Cxcl12, assay
380 ID Mm00445552_m1; Vegfa, assay ID Mm01281447_m1; Fgf2, assay ID Mm00433287_m1. mRNA
381 expression levels were normalized to B2m expression, assay ID Mm00437762_m1, and presented as
382 relative values.

383

384

385 ***In Vitro Assays***

386 Human dermal fibroblasts (HdFbs) (Life Technologies C0135C) and human dermal microvascular
387 endothelial cells (HdMVECs) (Life Technologies C01125PA) were purchased and used for *in vitro* assays.
388 All assays were conducted in triplicate unless otherwise stated.

389

390 ***Co-Culture***

391 Indirect co-culture experiments were performed using 6-well plates and 0.4 µM pore trans-well inserts.
392 HdFb were seeded in the upper chamber and HdMVECs were seeded in the lower chamber. si-CXCL12
393 and scrambled-siRNA were purchased from Life Technologies. HMVECs were transfected using
394 Lipofectamine RNAiMAX Reagent (Life Technologies) according to the manufacturer's protocol before
395 co-culture with HdFb in normoxia and hypoxia as previously described (Ceradini et al., n.d.).

396

397 ***Proliferation***

398 Human dermal fibroblasts were plated in 96-well cell-culture plates, 2500 cells/well, in 150 µL of medium
399 with 1% FBS. After 24 hours, fresh media with 1% FBS alone or with varying concentrations of
400 recombinant CXCL12 (25, 50, and 100 ng/mL) were added and after an additional 6 hours BrdU was
401 added and a cell proliferation assay was performed according to the manufacturer's instructions (Roche
402 Applied Sciences).

403

404 ***Migration***

405 Scratch assay was performed as previously described (Wang et al., 2018) on HdFb cultured in 24-well
406 plates with culture medium containing 1% FBS alone or with varying concentrations of recombinant
407 CXCL12 (25 and 100 ng/mL).

408 *Survival*

409 HdFb were cultured until 90% confluent in 24-well plates. They were then placed in culture medium
410 containing 1% FBS for 24 hours then cultured in medium containing 0.5% FBS alone, 100 ng/mL
411 recombinant CXCL12, 100 ng/mL recombinant CXCL12 + U0126 (Cell Signaling Technology), or 100
412 ng/mL recombinant CXCL12 + LY294002 (Cell Signaling Technology). After 72 hours, images of 5
413 HPFs/well were captured and recorded under phase contrast microscopy and manual cell counts were
414 performed by a blinded observer.

415

416 **Microfluidic Single-Cell Gene Expression Analysis**

417 Gene lists were collected from a literature search. Single cell reverse transcription and low cycle pre-
418 amplification were performed as previously described (Glotzbach et al., 2011; Januszyk et al., 2014).
419 Briefly, wound lysate cell suspensions were sorted from *Tie-2*^{Cre}/*CXCL12*^{loxP/loxP} and *CXCL12*^{loxP/loxP}
420 transgenic mice as single progenitor cells into each well of a 96-well plate using a Becton Dickinson
421 FACSAria flow cytometer (Franklin Lakes, NJ) into 6 µl of lysis buffer and SUPERase-In RNase
422 inhibitor (Applied Biosystems, Foster City, CA) (N=5 mice). Live/dead gating was performed based on
423 DAPI exclusion. Progenitor cells were defined as previously described. Reverse transcription and low
424 cycle pre-amplification were performed using Cells Direct (Invitrogen) with Taqman assay primer sets
425 (Applied Biosystems) as per the manufacturers specifications. Exon-spanning primers were used where
426 possible to avoid amplification of genomic background. cDNA was loaded onto 96.96 Dynamic Arrays
427 (Fluidigm, South San Francisco, CA) for qPCR amplification using Universal PCR Master Mix (Applied
428 Biosystems) with a uniquely compiled Taqman assay primer set (Supplementary Table 1) as previously
429 described (Glotzbach et al., 2011).

430

431 **Statistical Analysis**

432 For comparison between two groups, students t-tests were used with a P-value < 0.05 considered
433 statistically significant. Analysis of single cell data was performed as described previously (Glotzbach et
434 al., 2011; Januszyk et al., 2014; Levi et al., 2011). Briefly, data from all samples were normalized relative
435 to the pooled median expression for each gene and converted to base 2 logarithms. Absolute bounds (+/-
436 5 cycle thresholds from the median or 32-fold increases/decreases in expression) were set, and non-
437 expressers were assigned to this floor. Clustergrams were then generated using hierarchical clustering
438 (with a ‘complete’ linkage function and Euclidean distance metric) to facilitate data visualization
439 (MATLAB R2011b, MathWorks, Natick, MA).

440

441 To detect overlapping patterns within the single cell transcriptional data, k-means clustering was
442 employed using a standard Euclidean distance metric. Accordingly, each cell was assigned membership
443 to a specific cluster as dictated by similarities in expression profiles (minimizing the within-cluster sum
444 of square distances) in MATLAB. Optimally partitioned clusters were then sub-grouped using hierarchical
445 clustering to facilitate visualization of data patterning (Fukumura et al., 1998; Newman et al., 2011). Non-
446 parametric, two-sample Kolmogorov-Smirnov (K-S) tests were used to identify those genes with
447 expression patterns that differed significantly between population clusters and/or groups, following
448 Bonferroni correction for multiple samples using a strict cutoff of $p < 0.05$. For subgroup comparisons, the
449 empirical distribution of cells from each cluster was evaluated against that of the remaining cells in the
450 experiment. Ingenuity Pathway Analysis (IPA, Ingenuity Systems, Redwood City, CA) was used to
451 construct transcriptome networks based on genes that were significantly increased within clusters
452 (including both direct and indirect relationships).

453

454 **Data Sharing Statement**

455 Original data may be obtained by e-mail request to the corresponding author. Single cell transcriptional
456 data is available at GEO under accession number GSE146529.

457

458

459

460 **Acknowledgments**

461 We thank Theresa Carlomagno for administrative support and Yujin Park for help with tissue
462 processing.

463

464

465 **Competing interests:** The authors declare no conflicts of interest.

466

467

468

469 **References**

470

471 Arwert, E. N., Hoste, E., & Watt, F. M. (2012). Epithelial stem cells, wound healing and cancer. *Nature*
472 *Reviews. Cancer*, 12(3), 170–180. doi: 10.1038/nrc3217

473 Brem, H., & Tomic-Canic, M. (2007). Cellular and molecular basis of wound healing in diabetes. *The*
474 *Journal of Clinical Investigation*, 117(5), 1219–1222. doi: 10.1172/JCI32169

475 Bunster, E., & Meyer, R. K. (1933). An improved method of parabiosis. *The Anatomical Record*, 57(4),
476 339–343. doi: 10.1002/ar.1090570404

477 Campbell, J. J., Hedrick, J., Zlotnik, A., Siani, M. A., Thompson, D. A., & Butcher, E. C. (1998).
478 Chemokines and the arrest of lymphocytes rolling under flow conditions. *Science (New York,*
479 *N.Y.*), 279(5349), 381–384. doi: 10.1126/science.279.5349.381

480 Carmeliet, P., & Jain, R. K. (2011). Molecular mechanisms and clinical applications of angiogenesis.
481 *Nature*, 473(7347), 298–307. doi: 10.1038/nature10144

482 Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla,
483 J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (n.d.). Progenitor cell trafficking is
484 regulated by hypoxic gradients through HIF-1 induction of SDF-1. *Nature Medicine*, 10(8), 858–
485 864.

486 Chen, J., Zhang, Z. G., Li, Y., Wang, L., Xu, Y. X., Gautam, S. C., Lu, M., Zhu, Z., & Chopp, M.
487 (2003). Intravenous administration of human bone marrow stromal cells induces angiogenesis in
488 the ischemic boundary zone after stroke in rats. *Circulation Research*, 92(6), 692–699. doi:
489 10.1161/01.RES.0000063425.51108.8D

490 Ding, L., & Morrison, S. J. (2013). Haematopoietic stem cells and early lymphoid progenitors occupy
491 distinct bone marrow niches. *Nature*, 495(7440), 231–235. doi: 10.1038/nature11885

492 Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts,
493 E. W., Zhao, Q., Caballero, O. L., Teichmann, S. A., Janowitz, T., Jodrell, D. I., Tuveson, D. A.,
494 & Fearon, D. T. (2013). Targeting CXCL12 from FAP-expressing carcinoma-associated
495 fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. *Proceedings of the*
496 *National Academy of Sciences of the United States of America*, 110(50), 20212–20217. doi:
497 10.1073/pnas.1320318110

498 Flach, E. H., Rebecca, V. W., Herlyn, M., Smalley, K. S. M., & Anderson, A. R. A. (2011). Fibroblasts
499 contribute to melanoma tumor growth and drug resistance. *Molecular Pharmaceutics*, 8(6),
500 2039–2049. doi: 10.1021/mp200421k

501 Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986). Tumors: Wounds That Do Not Heal. *New England*
502 *Journal of Medicine*, 315(26), 1650–1659. doi: 10.1056/NEJM198612253152606

503 Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E. C., Lu, N., Selig, M., Nielsen, G., Taksir, T.,
504 Jain, R. K., & Seed, B. (1998). Tumor induction of VEGF promoter activity in stromal cells.
505 *Cell*, 94(6), 715–725. doi: 10.1016/s0092-8674(00)81731-6

506 Galiano, R. D., Michaels, V., Dobryansky, M., Levine, J. P., Gurtner, G. C., & others. (2004).
507 Quantitative and reproducible murine model of excisional wound healing. *Wound Repair and*
508 *Regeneration*, 12(4), 485–492.

509 Glotzbach, J. P., Januszyk, M., Vial, I. N., Wong, V. W., Gelbard, A., Kalisky, T., Thangarajah, H.,
510 Longaker, M. T., Quake, S. R., Chu, G., & Gurtner, G. C. (2011). An Information Theoretic,
511 Microfluidic-Based Single Cell Analysis Permits Identification of Subpopulations among
512 Putatively Homogeneous Stem Cells. *PLOS One*, 6(6), e21211. doi:
513 10.1371/journal.pone.0021211

514 Greenbaum, A., Hsu, Y.-M. S., Day, R. B., Schuettpelz, L. G., Christopher, M. J., Borgerding, J. N.,

515 Nagasawa, T., & Link, D. C. (2013). CXCL12 in early mesenchymal progenitors is required for

516 haematopoietic stem-cell maintenance. *Nature*, 495(7440), 227–230. doi: 10.1038/nature11926

517 Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. *Cell*, 144(5), 646–

518 674. doi: 10.1016/j.cell.2011.02.013

519 Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997). Interstitial pH and pO₂ gradients in solid

520 tumors in vivo: high-resolution measurements reveal a lack of correlation. *Nature Medicine*,

521 3(2), 177–182. doi: 10.1038/nm0297-177

522 Hida, K., Akiyama, K., Ohga, N., Maishi, N., & Hida, Y. (2013). Tumour endothelial cells acquire drug

523 resistance in a tumour microenvironment. *Journal of Biochemistry*, 153(3), 243–249. doi:

524 10.1093/jb/mvs152

525 Jaatinen, T., & Laine, J. (2007). Isolation of mononuclear cells from human cord blood by Ficoll-Paque

526 density gradient. *Current Protocols in Stem Cell Biology, Chapter 2, Unit 2A.1*. doi:

527 10.1002/9780470151808.sc02a01s1

528 Januszyk, M., Sorkin, M., Glotzbach, J. P., Vial, I. N., Maan, Z., Rennert, R. C., Duscher, D.,

529 Thangarajah, H., Longaker, M. T., Butte, A. J., & Gurtner, G. C. (2014). Diabetes Irreversibly

530 Depletes Bone Marrow-Derived Mesenchymal Progenitor Cell Subpopulations. *Diabetes*. doi:

531 10.2337/db13-1366

532 Kisanuki, Y. Y., Hammer, R. E., Miyazaki, J., Williams, S. C., Richardson, J. A., & Yanagisawa, M.

533 (2001). Tie2-Cre transgenic mice: a new model for endothelial cell-lineage analysis in vivo.

534 *Developmental Biology*, 230(2), 230–242. doi: 10.1006/dbio.2000.0106

535 Lawrence, M. B., & Springer, T. A. (1991). Leukocytes roll on a selectin at physiologic flow rates:
536 distinction from and prerequisite for adhesion through integrins. *Cell*, 65(5), 859–873. doi:
537 10.1016/0092-8674(91)90393-d

538 Levi, B., Wan, D. C., Glotzbach, J. P., Hyun, J., Januszyk, M., Montoro, D., Sorkin, M., James, A. W.,
539 Nelson, E. R., Li, S., Quarto, N., Lee, M., Gurtner, G. C., & Longaker, M. T. (2011). CD105
540 protein depletion enhances human adipose-derived stromal cell osteogenesis through reduction
541 of transforming growth factor β 1 (TGF- β 1) signaling. *The Journal of Biological Chemistry*,
542 286(45), 39497–39509. doi: 10.1074/jbc.M111.256529

543 Li, G., Satyamoorthy, K., Meier, F., Berking, C., Bogenrieder, T., & Herlyn, M. (2003). Function and
544 regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. *Oncogene*, 22(20),
545 3162–3171. doi: 10.1038/sj.onc.1206455

546 Mendt, M., & Cardier, J. E. (2017). Activation of the CXCR4 chemokine receptor enhances biological
547 functions associated with B16 melanoma liver metastasis. *Melanoma Research*, 27(4), 300–308.
548 doi: 10.1097/CMR.0000000000000346

549 Möhle, R., Rafii, S., & Moore, M. A. (1998). The role of endothelium in the regulation of hematopoietic
550 stem cell migration. *Stem Cells (Dayton, Ohio)*, 16 Suppl 1, 159–165. doi:
551 10.1002/stem.5530160819

552 Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S., Kitamura, Y., Yoshida, N.,
553 Kikutani, H., & Kishimoto, T. (1996). Defects of B-cell lymphopoiesis and bone-marrow
554 myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. *Nature*, 382(6592), 635–638.
555 doi: 10.1038/382635a0

556 Newman, A. C., Nakatsu, M. N., Chou, W., Gershon, P. D., & Hughes, C. C. W. (2011). The
557 requirement for fibroblasts in angiogenesis: fibroblast-derived matrix proteins are essential for

558 endothelial cell lumen formation. *Molecular Biology of the Cell*, 22(20), 3791–3800. doi:
559 10.1091/mbc.E11-05-0393

560 Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J.,
561 Richardson, A. L., & Weinberg, R. A. (2005). Stromal fibroblasts present in invasive human
562 breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12
563 secretion. *Cell*, 121(3), 335–348. doi: 10.1016/j.cell.2005.02.034

564 Patten, R. D., Aronovitz, M. J., Deras-Mejia, L., Pandian, N. G., Hanak, G. G., Smith, J. J., Mendelsohn,
565 M. E., & Konstam, M. A. (1998). Ventricular remodeling in a mouse model of myocardial
566 infarction. *American Journal of Physiology-Heart and Circulatory Physiology*, 274(5), H1812–
567 H1820. doi: 10.1152/ajpheart.1998.274.5.H1812

568 Schäfer, M., & Werner, S. (2008). Cancer as an overhealing wound: an old hypothesis revisited. *Nature
569 Reviews. Molecular Cell Biology*, 9(8), 628–638. doi: 10.1038/nrm2455

570 Stratman, A. N., Malotte, K. M., Mahan, R. D., Davis, M. J., & Davis, G. E. (2009). Pericyte
571 recruitment during vasculogenic tube assembly stimulates endothelial basement membrane
572 matrix formation. *Blood*, 114(24), 5091–5101. doi: 10.1182/blood-2009-05-222364

573 Suga, H., Rennert, R. C., Rodrigues, M., Sorkin, M., Glotzbach, J. P., Januszyk, M., Fujiwara, T.,
574 Longaker, M. T., & Gurtner, G. C. (2014). Tracking the Elusive Fibrocyte: Identification and
575 Characterization of Collagen-Producing Hematopoietic Lineage Cells During Murine Wound
576 Healing: Tracking Fibrocytes Without Surface Markers. *Stem Cells*, 32(5), 1347–1360. doi:
577 10.1002/stem.1648

578 Tachibana, K., Hirota, S., Iizasa, H., Yoshida, H., Kawabata, K., Kataoka, Y., Kitamura, Y.,
579 Matsushima, K., Yoshida, N., Nishikawa, S., Kishimoto, T., & Nagasawa, T. (1998). The

580 chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. *Nature*,
581 393(6685), 591–594. doi: 10.1038/31261

582 Teicher, B. A., & Fricker, S. P. (2010). CXCL12 (SDF-1)/CXCR4 pathway in cancer. *Clinical Cancer*
583 *Research: An Official Journal of the American Association for Cancer Research*, 16(11), 2927–
584 2931. doi: 10.1158/1078-0432.CCR-09-2329

585 Ubil, E., Duan, J., Pillai, I. C. L., Rosa-Garrido, M., Wu, Y., Bargiacchi, F., Lu, Y., Stanbouly, S.,
586 Huang, J., Rojas, M., Vondriska, T. M., Stefani, E., & Deb, A. (2014). Mesenchymal-endothelial
587 transition contributes to cardiac neovascularization. *Nature*, 514(7524), 585–590. doi:
588 10.1038/nature13839

589 Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018). Targeting the tumour stroma to improve
590 cancer therapy. *Nature Reviews. Clinical Oncology*, 15(6), 366–381. doi: 10.1038/s41571-018-
591 0007-1

592 Wagers, A. J., Sherwood, R. I., Christensen, J. L., & Weissman, I. L. (2002). Little evidence for
593 developmental plasticity of adult hematopoietic stem cells. *Science (New York, N.Y.)*, 297(5590),
594 2256–2259. doi: 10.1126/science.1074807

595 Wang, Y., Zheng, J., Han, Y., Zhang, Y., Su, L., Hu, D., & Fu, X. (2018). JAM-A knockdown
596 accelerates the proliferation and migration of human keratinocytes, and improves wound healing
597 in rats via FAK/Erk signaling. *Cell Death & Disease*, 9(9), 848. doi: 10.1038/s41419-018-0941-
598 y

599 Wong, V. W., Rustad, K. C., Galvez, M. G., Neofytou, E., Glotzbach, J. P., Januszyk, M., Major, M. R.,
600 Sorkin, M., Longaker, M. T., Rajadas, J., & others. (2010). Engineered pullulan–collagen
601 composite dermal hydrogels improve early cutaneous wound healing. *Tissue Engineering Part A*,
602 17(5–6), 631–644.

603 Zheng, B., Zhang, Z., Black, C. M., de Crombrugghe, B., & Denton, C. P. (2002). Ligand-dependent
604 genetic recombination in fibroblasts : a potentially powerful technique for investigating gene
605 function in fibrosis. *The American Journal of Pathology*, 160(5), 1609–1617. doi:
606 10.1016/S0002-9440(10)61108-X
607